Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension

Mi Seung Shin, Dae Ryong Kang, Changsoo Kim, Eun Joo Cho, Ki Chul Sung, Seok Min Kang, Dong Soo Kim, Seung Jae Joo, Seung Hwan Lee, Kyung Kuk Hwang, Jeong Bae Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. Methods: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30–120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). Results: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P,0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P,0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P,0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. Conclusion: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.

Original languageEnglish
Pages (from-to)1573-1580
Number of pages8
JournalDrug Design, Development and Therapy
Volume10
DOIs
Publication statusPublished - 2016 May 5

Fingerprint

Blood Pressure
Hypertension
fimasartan
Angiotensin Receptor Antagonists
Therapeutics
Body Mass Index
Regression Analysis
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Shin, Mi Seung ; Kang, Dae Ryong ; Kim, Changsoo ; Cho, Eun Joo ; Sung, Ki Chul ; Kang, Seok Min ; Kim, Dong Soo ; Joo, Seung Jae ; Lee, Seung Hwan ; Hwang, Kyung Kuk ; Park, Jeong Bae. / Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. In: Drug Design, Development and Therapy. 2016 ; Vol. 10. pp. 1573-1580.
@article{a469803ab82844fba8a65ef43eaa3a56,
title = "Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension",
abstract = "Background: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. Methods: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6{\%}) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30–120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). Results: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P,0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P,0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P,0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. Conclusion: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.",
author = "Shin, {Mi Seung} and Kang, {Dae Ryong} and Changsoo Kim and Cho, {Eun Joo} and Sung, {Ki Chul} and Kang, {Seok Min} and Kim, {Dong Soo} and Joo, {Seung Jae} and Lee, {Seung Hwan} and Hwang, {Kyung Kuk} and Park, {Jeong Bae}",
year = "2016",
month = "5",
day = "5",
doi = "10.2147/DDDT.S107433",
language = "English",
volume = "10",
pages = "1573--1580",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension. / Shin, Mi Seung; Kang, Dae Ryong; Kim, Changsoo; Cho, Eun Joo; Sung, Ki Chul; Kang, Seok Min; Kim, Dong Soo; Joo, Seung Jae; Lee, Seung Hwan; Hwang, Kyung Kuk; Park, Jeong Bae.

In: Drug Design, Development and Therapy, Vol. 10, 05.05.2016, p. 1573-1580.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension

AU - Shin, Mi Seung

AU - Kang, Dae Ryong

AU - Kim, Changsoo

AU - Cho, Eun Joo

AU - Sung, Ki Chul

AU - Kang, Seok Min

AU - Kim, Dong Soo

AU - Joo, Seung Jae

AU - Lee, Seung Hwan

AU - Hwang, Kyung Kuk

AU - Park, Jeong Bae

PY - 2016/5/5

Y1 - 2016/5/5

N2 - Background: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. Methods: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30–120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). Results: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P,0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P,0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P,0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. Conclusion: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.

AB - Background: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a previous large population study. The purpose of this study was to evaluate whether fimasartan treatment for 3 months affects clinical and home BP variability in addition to reducing BP. Methods: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with mild-to-moderate hypertension who had a complete set of home BP measurements (morning and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone was used to control BP at a daily dose of 30–120 mg. Clinical and home BP measurements were performed before and after the 3-month treatment. BP variability included beat-to-beat variability (clinical) and day-to-day variability (home). Results: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical systolic BP (c-SBP) was 15.08±18.36 mmHg (P,0.0001), and the average reduction of morning home SBP (m-SBP) was 11.49±19.33 mmHg (P,0.0001). Beat-to-beat variability as standard deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P,0.0001). Multiple regression analysis revealed an independent association between the change in the SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass index, and change in mean BP. Conclusion: This study indicated that 3 months of fimasartan treatment reduced day-to-day BP variability independent of BP reduction in patients with hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84966839268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966839268&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S107433

DO - 10.2147/DDDT.S107433

M3 - Article

C2 - 27217724

AN - SCOPUS:84966839268

VL - 10

SP - 1573

EP - 1580

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -